We are live on !
Find out more
Andera Partners Portfolio holdings
AUM
$176M
Turnover
12.5%
1-Year Est. Return
1.8%
This Fund
S&P 500
This Quarter Est. Return
+8.14%
1 Year Est. Return
+1.8%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$206M
AUM Growth
+$29.6M
(+17%)
Cap. Flow
+$24.5M
Cap. Flow % of AUM
Cap. Flow %
11.87%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
2
Reduced
1
Closed
–
Avg Time Held
0.4
years
Top 10 Avg Time Held
0.4
years
Top 20 Avg Time Held
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avalyn Pharma
AVLN
|
+$26.8M |
| 2 |
Inventiva
IVA
|
+$8.72M |
| 3 |
Kestra Medical Technologies
KMTS
|
+$701K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Evommune Inc
EVMN
|
+$11.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Kestra Medical Technologies
KMTS
$1.71B
| $69.4M | 33.62% |
2,728,679
+33,487
| +1% | +$701K |
2025 Q4
2 quarters
|
|
2
Mineralys Therapeutics
MLYS
$1.36B
| $42.9M | 20.8% |
1,591,917
| – | – |
2025 Q4
2 quarters
|
|
|
3
Avalyn Pharma
AVLN
$1.34B
| $30.6M | 14.82% |
+929,824
| New | +$26.8M |
2026 Q2
0 quarters
|
|
4
AgomAb Therapeutics NV
AGMB
$313M
| $20M | 9.67% |
1,538,702
| – | – |
2026 Q1
1 quarter
|
|
|
5
Evommune Inc
EVMN
$277M
| $18.5M | 8.96% |
1,391,990
-505,372
| -27% | -$11.7M |
2025 Q4
2 quarters
|
|
|
6
Inventiva
IVA
$880M
| $13.7M | 6.65% |
3,633,181
+1,815,000
| +100% | +$8.72M |
2025 Q4
2 quarters
|
|
7
Abivax
ABVX
$7.67B
| $10.4M | 5.04% |
78,125
| – | – |
2025 Q4
2 quarters
|
|
8
Nyxoah
NYXH
$91.6M
| $882K | 0.43% |
522,057
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
SV
CMP
Andera Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Andera Partners held 8 positions worth $206M, up 17% from $177M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Andera Partners deployed $24.5M of net new capital in Q2 2026, opening 1 new position and adding to 2 existing holdings. Its largest new stake was Avalyn Pharma: 929,824 shares worth $30.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Evommune Inc, an estimated $11.7M trimmed.
- Andera Partners's largest Q2 2026 buy was Avalyn Pharma: 929,824 shares worth $30.6M.
- Andera Partners added most to Inventiva in Q2 2026, an estimated $8.72M increase.
- Andera Partners's biggest Q2 2026 reduction was Evommune Inc, cutting an estimated $11.7M.
- Andera Partners's ten largest holdings make up 100% of its $206M portfolio in Q2 2026.
- Andera Partners opened 1 new position and closed 0 in Q2 2026.
- Andera Partners's portfolio value rose 17% quarter-over-quarter to $206M.
Based on Andera Partners's 13F filing for Q2 2026, filed 22 Jul 2026.